Allergy Therapeutics (HHU) Stock Statistics & Valuation Metrics
Total Valuation
Allergy Therapeutics has a market cap or net worth of EUR 302.84M. The enterprise value is EUR 591.39M.
- Market Cap
- EUR 302.84M
- Enterprise Value
- EUR 591.39M
Share Statistics
Allergy Therapeutics has 6,332,530,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 6,332,530,000
- Owned by Insiders
- ―
- Owned by Institutions
- 0.09%
Financial Efficiency
Allergy Therapeutics’s return on equity (ROE) is 1.42 and return on invested capital (ROIC) is -69.33%.
- Return on Equity (ROE)
- 1.42
- Return on Assets (ROA)
- -0.59
- Return on Invested Capital (ROIC)
- -69.33%
- Return on Capital Employed (ROCE)
- -0.73
- Revenue Per Employee
- 94.25K
- Profits Per Employee
- -68.72K
- Employee Count
- 584
- Asset Turnover
- 0.81
- Inventory Turnover
- 2.15
Valuation Ratios
The current PE Ratio of Allergy Therapeutics is -4.04. Allergy Therapeutics’s PEG ratio is 0.29.
- PE Ratio
- -4.04
- PS Ratio
- 4.42
- PB Ratio
- 49.19
- Price to FCF
- -6.78
- Price to Operating Cash Flow
- -6.37
- PEG Ratio
- 0.29
Income Statement
In the last 12 months, Allergy Therapeutics had revenue of 55.04M and earned -40.13M in profits. Earnings per share was -0.01.
- Revenue
- 55.04M
- Gross Profit
- 25.13M
- Operating Income
- -29.50M
- Pretax Income
- -40.44M
- Net Income
- -40.13M
- EBITDA
- -29.43M
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -32.80M and capital expenditures -4.55M, giving a free cash flow of -37.34M billion.
- Operating Cash Flow
- -32.80M
- Free Cash Flow
- -37.34M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Allergy Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -14.74%
- Earnings Yield
- -23.43%
Stock Price Statistics
- Beta
- 0.57
- 52-Week Price Change
- -54.65%
- 50-Day Moving Average
- 0.05
- 200-Day Moving Average
- 0.09
- Relative Strength Index (RSI)
- 26.96
- Average Volume (3m)
- 58.79K
Important Dates
Allergy Therapeutics upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 24, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Allergy Therapeutics as a current ratio of 1.28, with Debt / Equity ratio of -213.13%
- Current Ratio
- 1.28
- Quick Ratio
- 0.76
- Debt to Market Cap
- 0.14
- Net Debt to EBITDA
- -1.61
- Interest Coverage Ratio
- -4.31
Taxes
In the past 12 months, Allergy Therapeutics has paid -312.00K in taxes.
- Income Tax
- -312.00K
- Effective Tax Rate
- 0.01
Enterprise Valuation
Allergy Therapeutics EV to EBITDA ratio is -8.25, with an EV/FCF ratio of -7.23.
- EV to Sales
- 4.71
- EV to EBITDA
- -8.25
- EV to Free Cash Flow
- -7.23
- EV to Operating Cash Flow
- -8.23
Balance Sheet
Allergy Therapeutics has EUR 10.08M in cash and marketable securities with EUR 26.75M in debt, giving a net cash position of -EUR 16.67M billion.
- Cash & Marketable Securities
- EUR 10.08M
- Total Debt
- EUR 26.75M
- Net Cash
- -EUR 16.67M
- Net Cash Per Share
- EUR 0.00
- Tangible Book Value Per Share
- EUR 0.00
Margins
Gross margin is 41.17%, with operating margin of -60.23%, and net profit margin of -85.46%.
- Gross Margin
- 41.17%
- Operating Margin
- -60.23%
- Pretax Margin
- -84.50%
- Net Profit Margin
- -85.46%
- EBITDA Margin
- -57.12%
- EBIT Margin
- -64.79%
Analyst Forecast
The average price target for Allergy Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 1.09%
- EPS Growth Forecast
- -31.82%
Scores
- Smart Score
- 3
- AI Score
- ―